Colorectal cancer is the third leading cause of cancer-related deaths in the United States when men and women are considered separately, and the second leading cause when both sexes are combined. The American Cancer Society estimates that there will be over 95,200 new cases of colon cancer and 39,200 new cases of rectal cancer in the United States in 2016.
Etubics colorectal cancer immunotherapy targets CEA expressing colorectal cancer cells. CEA represents an attractive target antigen for immunotherapy since it is over-expressed in nearly all colorectal cancers and many pancreatic cancers, 70% of non-small cell lung cancers and approximately 50% of breast cancers. Etubics’ colorectal cancer immunotherapeutic product candidate has completed Phase I/II clinical trials at Duke University Medical Center in Durham, North Carolina and Medical Oncology Associates, in Spokane, Washington. Etubics clinical trials have been funded entirely by the National Cancer Institute (NCI), through their peer-reviewed granting and contract process. To date, Etubics has been very encouraged by the clinical outcome of ETBX-011 and no safety issues or adverse effects have been reported in either animal or human studies. The ETBX-011 Stage IV patients treated in our trials tended to exhibit survival that was longer than would be expected for patients with refectory progressive metastatic colorectal cancer.